Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$72.00K$72.00K−71.9% vs Q2 2022 Net Income-$55.06M-$55.06MN/M vs Q2 2022 EPS Diluted-$1.27-$1.27N/M vs Q2 2022 Operating Income-$59,275,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$45,545,000N/M Margins · derivedOperating margin-82326.4%−70778.0 pt vs Q2 2022
Net margin-76476.4%−64956.5 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 8, 2023 · 39 d after period end